Overview of research on fusion genes in prostate cancer

Prostate cancer (PCa) was the second most common malignant tumor of men worldwide with 899,000 new cases each year, accounted for 14% of all cancers. And it was the sixth cause of cancer-related death in men, especially in developed countries (1,2). It had the highest incidence in Australia, Europe and Northern America, and was also high in the African descent, Southern America and the Caribbean regions. In Asia, however, PCa accounted for only 1–10% of male tumor cases (3). In recent years, the incidence of PCa in China had been rising dramatically year by year. In Beijing, Shanghai and Guangzhou, the incidence of PCa had surpassed that of male bladder cancer, ranking first among male genitourinary tumors (4)